

08 Jan 2019 | News

QUOTED. Jan. 8, 2019. Johnathan Lancaster.

by

The UK's National Institute for Health and Care Excellence (NICE) added Myriad Genetics' *EndoPredict* test to its recommendations for breast-cancer treatment as new data show the long-term prognostic value of the EndoPredict test in guiding therapy for many of these patients. See what the firm's chief medical officer has to say about it here.

"Hopefully it will be a game-changing offering to the clinical market place and I'm highly optimistic that this is going to be incredibly well received and will be a source of improvements in outcomes for patients." – Johnathan Lancaster, chief medical officer, Myriad Genetics

- Find out more: [Myriad Finishes Big Year With NICE Endorsement Of EndoPredict Breast Cancer Diagnostic](#)

[Click here](#) for a free trial of *Medtech Insight*.